Senestech, Inc. (NASDAQ:SNES) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “

Shares of Senestech (SNES) opened at 2.14 on Tuesday. The company’s 50 day moving average price is $1.86 and its 200-day moving average price is $1.86. Senestech has a 1-year low of $1.54 and a 1-year high of $10.69. The firm’s market cap is $22.10 million.

Senestech (NASDAQ:SNES) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.10 million. Equities analysts expect that Senestech will post ($1.30) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Senestech, Inc. (SNES) Stock Rating Lowered by Zacks Investment Research” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/03/senestech-inc-snes-stock-rating-lowered-by-zacks-investment-research.html.

In other news, COO Andrew Altman bought 20,000 shares of the firm’s stock in a transaction on Friday, August 18th. The stock was bought at an average cost of $2.77 per share, for a total transaction of $55,400.00. Following the completion of the acquisition, the chief operating officer now directly owns 2,600 shares in the company, valued at approximately $7,202. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Julia Ann Williams bought 10,000 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was purchased at an average price of $3.21 per share, with a total value of $32,100.00. Following the completion of the acquisition, the director now owns 11,950 shares of the company’s stock, valued at $38,359.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 54,100 shares of company stock worth $155,730 and sold 19,411 shares worth $46,073. Insiders own 27.40% of the company’s stock.

A hedge fund recently raised its stake in Senestech stock. Prudential PLC increased its position in shares of Senestech, Inc. (NASDAQ:SNES) by 49.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 447,971 shares of the company’s stock after acquiring an additional 147,971 shares during the quarter. Prudential PLC owned 4.39% of Senestech worth $2,661,000 as of its most recent SEC filing. Institutional investors own 15.34% of the company’s stock.

About Senestech

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Receive News & Stock Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related stocks with our FREE daily email newsletter.